Trial Profile
Long term outcome with trastuzumab in HER2-positive metastatic breast cancer: A retrospective analysis at The Royal Marsden Hospital, with a median 6 years follow up
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Apr 2014
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary)
- Indications Breast cancer; Male breast cancer
- Focus Therapeutic Use
- 22 Apr 2014 New trial record